- Home
- SLGL vs TENX Comparison
SLGL vs TENX Comparison
Compare SLGL & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | TENX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 56.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLGL | TENX |
|---|---|---|
| Price | $44.02 | $10.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $50.00 | $17.00 |
| AVG Volume (30 Days) | 15.4K | ★ 153.4K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,970,000.00 | N/A |
| Revenue This Year | $121.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 62.04 | N/A |
| 52 Week Low | $4.02 | $4.63 |
| 52 Week High | $52.26 | $10.65 |
Technical Indicators
Market Signals| Indicator | SLGL | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 73.08 |
| Support Level | $38.37 | $9.40 |
| Resistance Level | $43.90 | $10.55 |
| Average True Range (ATR) | 4.01 | 0.60 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 41.27 | 88.74 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.